Stock Research: Novozymes

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Novozymes

CPSE:NZYM B DK0060336014
57
  • Value
    62
  • Growth
    81
  • Safety
    Safety
    4
  • Combined
    49
  • Sentiment
    61
  • 360° View
    360° View
    57
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Novozymes A/S is a biotechnology company that produces and sells industrial enzymes, microorganisms, and biopharmaceutical ingredients. It operates in agriculture, bioenergy, food & beverages, household care, and more. The company's main regions are Europe, Middle East & Africa, North America, Asia Pacific, and Latin America. In the last fiscal year, the company had a market cap of $32,679 million, profits of $1,873 million, revenue of $3,969 million, and 10,582 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 57 (better than 57% compared with alternatives), overall professional sentiment and financial characteristics for the stock Novozymes are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Novozymes. The consolidated Growth Rank has a good rank of 81, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 81% of competitors in the same industry. The consolidated Safety Rank at 62 means that the company has a financing structure that is safer than 62% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 61, which means that professional investors are more optimistic about the stock than for 61% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 4, meaning that the share price of Novozymes is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 96% of alternative stocks in the same industry. ...read more

more
Index
OMX C20
Low Emissions
Human Rights
Renewables Users
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 6 3 3
Growth
81 92 45 21
Safety
Safety
62 46 62 68
Sentiment
61 80 100 83
360° View
360° View
57 60 59 25
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
57 56 56 1
Opinions Change
8 41 87 50
Pro Holdings
n/a 60 100 83
Market Pulse
97 84 93 98
Sentiment
61 80 100 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
4 6 3 3
Growth
81 92 45 21
Safety Safety
62 46 62 68
Combined
49 51 20 16
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
10 7 5 1
Price vs. Earnings (P/E)
3 3 5 7
Price vs. Book (P/B)
17 16 1 1
Dividend Yield
34 33 40 44
Value
4 6 3 3
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
87 87 60 42
Profit Growth
56 73 57 23
Capital Growth
88 73 11 31
Stock Returns
41 65 65 71
Growth
81 92 45 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
84 44 59 77
Refinancing
9 8 14 8
Liquidity
69 90 100 90
Safety Safety
62 46 62 68

Similar Stocks

Discover high‑ranked alternatives to Novozymes and broaden your portfolio horizons.

Continental

XTRA:CON
Country: Germany
Industry: Auto Parts & Equipment
Size: X-Large
Full Stock Analysis

Polski Koncern Naftowy ORLEN Spolka Akcyjna

WSE:PKN
Country: Poland
Industry: Oil & Gas Refining
Size: X-Large
Full Stock Analysis

thyssenkrupp

XTRA:TKA
Country: Germany
Industry: Steel
Size: X-Large
Full Stock Analysis

Daimler Truck

XTRA:DTG
Country: Germany
Industry: Heavy Machinery
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.